Literature DB >> 16810199

MN1-TEL, the product of the t(12;22) in human myeloid leukemia, immortalizes murine myeloid cells and causes myeloid malignancy in mice.

C Carella1, J Bonten, J Rehg, G C Grosveld.   

Abstract

MN1-TEL is the product of the recurrent t(12;22)(p12;q11) associated with human myeloid malignancies. MN1-TEL functions as an activated transcription factor, exhibiting weak transforming activity in NIH3T3 fibroblasts that depends on the presence of a functional TEL DNA-binding domain, the N-terminal transactivating sequences of MN1 and C-terminal sequences of MN1. We determined the transforming activity of MN1-TEL in mouse bone marrow (BM) by using retroviral transfer. MN1-TEL-transduced BM showed increased self-renewal capacity of primitive progenitors in vitro, and prolonged in vitro culture of MN1-TEL-expressing BM produced immortalized myeloid, interleukin (IL)-3/stem cell factor-dependent cell lines with a primitive morphology. Transplantation of such cell lines into lethally irradiated mice rescued them from irradiation-induced death and resulted in the contribution of MN1-TEL-expressing cells to all hematopoietic lineages, underscoring the primitive nature of these cells and their capacity to differentiate in vivo. Three months after transplantation, all mice succumbed to promonocytic leukemia. Transplantation of freshly MN1-TEL-transduced BM into lethally irradiated mice also caused acute myeloid leukemia within 3 months of transplantation. We infer that MN1-TEL is a hematopoietic oncogene that stimulates the growth of hematopoietic cells, but depends on secondary mutations to cause leukemia in mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16810199     DOI: 10.1038/sj.leu.2404298

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  Meningioma 1 is required for appropriate osteoblast proliferation, motility, differentiation, and function.

Authors:  Xiaoxue Zhang; Diane R Dowd; Meika C Moore; Tanya A Kranenburg; Magda A Meester-Smoor; Ellen C Zwarthoff; Paul N MacDonald
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

2.  Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

Authors:  Christian Langer; Guido Marcucci; Kelsi B Holland; Michael D Radmacher; Kati Maharry; Peter Paschka; Susan P Whitman; Krzysztof Mrózek; Claudia D Baldus; Ravi Vij; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

3.  The Mn1 transcription factor acts upstream of Tbx22 and preferentially regulates posterior palate growth in mice.

Authors:  Wenjin Liu; Yu Lan; Erwin Pauws; Magda A Meester-Smoor; Philip Stanier; Ellen C Zwarthoff; Rulang Jiang
Journal:  Development       Date:  2008-10-23       Impact factor: 6.868

4.  MN1 affects expression of genes involved in hematopoiesis and can enhance as well as inhibit RAR/RXR-induced gene expression.

Authors:  Magda A Meester-Smoor; Marjolein J F W Janssen; Gerard C Grosveld; Annelies de Klein; Wilfred F J van IJcken; Hannie Douben; Ellen C Zwarthoff
Journal:  Carcinogenesis       Date:  2008-07-16       Impact factor: 4.944

5.  Mapping of MN1 sequences necessary for myeloid transformation.

Authors:  Ayten Kandilci; Jacqueline Surtel; Laura Janke; Geoffrey Neale; Sabrina Terranova; Gerard C Grosveld
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

6.  The BAFfling story of MN1-induced leukemogenesis.

Authors:  Aaron J Stonestrom; Ross L Levine
Journal:  Mol Cell       Date:  2021-06-03       Impact factor: 19.328

7.  The leukemia-associated fusion protein MN1-TEL blocks TEL-specific recognition sequences.

Authors:  W Martijn ter Haar; Magda A Meester-Smoor; Karel H M van Wely; Claudia C M M Schot; Marjolein J F W Janssen; Bart Geverts; Jacqueline Bonten; Gerard C Grosveld; Adriaan B Houtsmuller; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

Review 8.  Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.

Authors:  M Mimeault; R Hauke; P P Mehta; S K Batra
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.